Grünenthal Challenge: Cell-Based/Gene Therapies for Pain – Innovita Research

Pain is an unpleasant sensation that is part of the body’s protective mechanism designed to give a warning of potential or actual tissue damage. When pain is not managed effectively, it can persist and become debilitating, resulting in an overwhelming burden of suffering and poor quality of life. Due to the complexity of chronic pain, the Seeker is seeking proposals for alternative cell-based/gene editing approaches to deliver more effective therapies.

An illustration depicting neck pain. Image credit: Injurymap via Wikipedia/CC BY-SA 4.0

This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.


Across the globe, chronic pain is a source of considerable suffering and disability, with significant economic, physical, psychological, and social consequences. Chronic pain can be associated with an injury or disease, but in other cases, there may be no clear cause. Although moderate to severe pain can be relieved with prescription pain relievers, misuse and addiction to opioids is a growing problem. The Seeker is committed to pain research and providing innovative and reliable medications for patients. Successful proposals will include compelling evidence of potent and reproducible pain modulation.

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 30, 2019.

About The Seeker

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

Source: InnoCentive